Form 4: DENTSPLY SIRONA SVP Awarded Equity

DENTSPLY SIRONA's SVP and CHRO, Andrea L. Frohning, received an equity award comprising Restricted Stock Units and stock options.

Summary

• Andrea L. Frohning, SVP, CHRO of DENTSPLY SIRONA Inc. (XRAY), was granted an equity award on March 4, 2026.
• The award includes 26,786 Restricted Stock Units (RSUs) which vest in annual one-third increments over three years, ending March 4, 2029.
• Additionally, 121,600 stock options were granted with an exercise price of $14.78, vesting in annual one-third increments over three years, ending March 4, 2029, and expiring on March 4, 2036.
• The exercise price for the stock options is 110% of the closing price of the company's common stock on the grant date.
• Following these transactions, Frohning beneficially owns 63,992.252 shares of common stock and 121,600 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retaining key talent and aligning management incentives with long-term shareholder value creation.

Positives

• The equity award aligns management's interests with shareholder value creation through performance-based vesting.
• The grant of 26,786 Restricted Stock Units (RSUs) and 121,600 stock options serves as a retention incentive for a key executive.
• The stock option exercise price being 110% of the grant date closing price indicates a performance hurdle for value realization.

Future Outlook

The equity awards, consisting of Restricted Stock Units and stock options, are structured to vest in annual one-third increments over a three-year period, concluding on March 4, 2029, indicating a long-term incentive and retention strategy for the executive.

Industry Context

StockSavvy.ai notes that equity awards, particularly those with multi-year vesting schedules and performance-based exercise prices (like 110% of grant date closing price), are standard practice in the healthcare and dental equipment industry for executive compensation. This aligns DENTSPLY SIRONA with common industry practices for executive retention and incentivization, similar to peers like Align Technology or Zimmer Biomet, who also utilize long-term incentive plans to motivate leadership.

Comparison to Industry Standards

• The multi-year vesting schedule (three years) for both RSUs and stock options is consistent with typical executive long-term incentive plans across the healthcare and medical device sectors, aiming for executive retention and alignment with long-term company performance.
• The stock option exercise price set at 110% of the closing price on the grant date is a common practice for premium options, requiring the stock price to appreciate beyond the grant date value for the options to be in-the-money, similar to structures seen in companies like Medtronic or Stryker for their executive awards.
• The overall size of the award for an SVP, CHRO role appears to be within the expected range for a company of DENTSPLY SIRONA's market capitalization, comparable to compensation packages at similar-sized medical technology firms.

Stakeholder Impact

• Shareholders: The award aligns executive incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.
• Management: Provides significant long-term incentive and compensation for the SVP, CHRO.

Next Steps

• The Restricted Stock Units will vest in annual one-third increments over three years, with the final vesting on March 4, 2029.
• The Stock Options will become exercisable in annual one-third increments over three years, with the final vesting on March 4, 2029, and will expire on March 4, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation award to a senior executive, which is a standard practice for executive retention and incentive alignment. It does not provide new information that would fundamentally alter the investment thesis for DENTSPLY SIRONA, nor does it suggest any immediate catalysts for significant price movement. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

DENTSPLY SIRONA, XRAY, Andrea L. Frohning, SVP CHRO, Restricted Stock Units, RSUs, Stock Options, Equity Award, Insider Transaction, Executive Compensation, SEC Form 4